Efficacy and Safety of Imatinib in Scleroderma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

December 31, 2010

Conditions
Scleroderma, LocalizedScleroderma, Systemic
Interventions
DRUG

imatinib mesylate

6 month treatment with 400mg/day (per os)

Trial Locations (12)

24000

Service de Dermatologie - CHG Périgueux, Périgueux

33076

Service de Dermatologie et services de médecine interne et vasculaire - Hôpital St André - CHU de Bordeaux, Bordeaux

Service de Rhumatologie, Hôpital Pellegrin-Tondu CHU de Bordeaux, Bordeaux

33500

Service de Dermatologie - CHG Libourne, Libourne

33604

Service de Dermatologie - service de médecine interne et vasculaire - hopital haut Lévêque - av.de magellan, Pessac

37044

Service de Médecine interne - CHU de Tours, Tours

54035

Service de Médecin interne - Hôpital central, Nancy

59322

Néphrologie et Médecine interne - CH de Valenciennes, Valenciennes

67098

Service de Rhumatologie - CHU de Strasbourg, Strasbourg

75475

Service de Médecine interne - Hôpital Saint Louis, Paris

87042

Service de dermatologie - CHU de Limoges, Limoges

31059 Toulouse Cedex

Service de Dermatologie - CHU de Toulouse - Hopital Purpan, Toulouse

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

Novartis

INDUSTRY

lead

University Hospital, Bordeaux

OTHER

NCT00479934 - Efficacy and Safety of Imatinib in Scleroderma | Biotech Hunter | Biotech Hunter